Opus Point Partners Management’s Akebia Therapeutics AKBA Stock Holding History

Opus Point Partners Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-45,004	Closed	-$397K	–	41
2018 Q3	$397K	Sell	45,004 -5,000	-10%	-$44.7K	0.95%	34
2018 Q2	$499K	Hold	50,004	–	–	1.08%	26
2018 Q1	$477K	Buy	50,004 +28,995	+138%	+$406K	0.94%	29
2017 Q4	$312K	Hold	21,009	–	–	0.27%	47
2017 Q3	$413K	Hold	21,009	–	–	0.37%	54
2017 Q2	$302K	Sell	21,009 -21,010	-50%	-$266K	0.28%	52
2017 Q1	$387K	Buy	+42,019	New	+$410K	0.29%	55

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Opus Point Partners Management's AKBA Position: Q4 2018 in Review

Opus Point Partners Management sold out of Akebia Therapeutics (AKBA) in Q4 2018, closing a stake of 45,004 shares — an estimated $397K sold.

Opus Point Partners Management first reported a position in AKBA in Q1 2017 and held it in 7 quarters. The position peaked at $499K in Q2 2018. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

Opus Point Partners Management reported no remaining Akebia Therapeutics position as of Q4 2018 after selling out during the quarter.
Opus Point Partners Management sold 45,004 Akebia Therapeutics shares in Q4 2018, an estimated $397K.
Opus Point Partners Management first reported a position in Akebia Therapeutics in Q1 2017 and held it in 7 quarters.
Opus Point Partners Management's Akebia Therapeutics position peaked at $499K in Q2 2018.
166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.